Close

Anti-CD10 TCR-ABR-3δ (XW-647) CAR Vector (XS-1122-YF4327)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD10 TCR-fused Antigen Binding Receptor (TCR-ABR) CAR is constructed for the engineering of T cells to target Mouse CD10. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv (XW-647) of anti-CD10 antibody linked to CD3δ subunit. The vector product was designed for the discovery and development of cellular therapy against Acute myeloid leukemia (AML). The TCR-ABR can effectively reprogram an intact TCR complex to recognize tumor surface antigens. TCR-ABR-T cells are shown to engage the signaling capacity of the entire TCR complex in an HLA-independent manner.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD10
  • Targeting Cell Type
  • T Cell
  • Targeting Diseases
  • Acute myeloid leukemia (AML)
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-CD3δ
  • Discription of Signaling Cassetes
  • The scFv used to generate CAR-T cells or single domain antibodies can be fused to the extracellular N-termini of TCRα, TCRβ, CD3γ, CD3δ, or CD3ε subunits, resulting in the activation of target-specific TCR-ABR-T cells. TCR-ABR-T cells have been shown to use the entire TCR complex's signaling capacity in an HLA-independent manner.

Target

  • Clone
  • XW-647
  • Host
  • Rat
  • Target Species
  • Mouse
  • Gene Name
  • membrane metalloendopeptidase
  • Synonyms
  • CALLA, CD10, CMT2T, NEP, SCA43, SFE
  • Introduction
  • The protein encoded by this gene is a type II transmembrane glycoprotein and a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). The encoded protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL. This protein is not restricted to leukemic cells, however, and is found on a variety of normal tissues. The protein is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD10 TCR-ABR (scFv-CD3δ, XW-647) CAR Plasmid, pCDCAR1 (XS-1122-YF4327). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.